Abstract |
Acute exacerbation is the major cause of asthma morbidity, mortality, and health-care costs. Respiratory viral infections, particularly rhinovirus (RV) infections, are associated with the majority of asthma exacerbations. The risk for bronchoconstriction with RV is associated with allergic sensitization and type 2 airway inflammation. The efficacy of the humanized anti-IgE monoclonal antibody omalizumab in treating asthma and reducing the frequency and severity of RV-induced asthma exacerbation is well-known. Despite these clinical data, mechanistic details of omalizumab's effects on RV-induced asthma exacerbation have not been well-defined for years due to the lack of appropriate animal models. In this Perspective, we discuss potential IgE-dependent roles of mast cells and dendritic cells in asthma exacerbations.
|
Authors | Toshiaki Kawakami, Kazumi Kasakura, Yu Kawakami, Tomoaki Ando |
Journal | Frontiers in allergy
(Front Allergy)
Vol. 3
Pg. 835748
( 2022)
ISSN: 2673-6101 [Electronic] Switzerland |
PMID | 35386658
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 Kawakami, Kasakura, Kawakami and Ando. |